BioSpace News Archive

Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Anders Götzsche to its Board of Directors

As part of the preparations for a potential offering of American Depository Shares in the United States and a concurrent listing on the Nasdaq Global Market in the United States, the extraordinary general meeting resolved to, in accordance with the board of directors’ proposal, authorize the board of directors to, at one or several occasions and for the period up until the next annual general meeting

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.

Intraprise Health announced that Ryan Patrick, Senior Vice President of Security Products, and Melissa Hawkins, Information Security Team Lead, have again been named as members of the 2020 HITRUST External Assessor Council.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced preliminary unaudited net product revenue for the fourth quarter of 2019 and interim results from its Phase 1 clinical trial for OTX-TKI,

Attendees at HIMSS20 who want to learn how analytics, artificial intelligence (AI) and machine learning (ML) can be used more easily and effectively to achieve peak business health will want to stop by the VisiQuate Innovation Live booth, #8200-38 (Hall E).

Science Applications International Corporation (NYSE:SAIC), a leading technology integrator providing full life cycle services and solutions in the technical, engineering, intelligence, and enterprise information technology markets, is scheduled to issue its fourth quarter and full fiscal year 2020 results and hold a conference call after close of market on Thursday, March 26, 2020.

Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co founder and chief executive officer of Invitae, will present at Oppenheimer’s 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 1:00 p.m. Eastern in New York City.

PHOENIX Rehabilitation & Health Services, has signed a definitive agreement to acquire Colorado Athletic Conditioning Clinic, expanding the company’s geographic reach to Colorado.